Integrating Therapeutic Advances to Improve Current Practices in Myeloma Patient Care

Access Activity

Overview / Abstract:

Improving outcomes for patients with multiple myeloma requires building on the foundation of current therapies with new agents and combinations, recognizing the nature of each individual patient’s disease, and providing a personalized approach to treatment. This activity uses evidence-based presentations and case study vignettes to present the latest information on selecting the most appropriate therapy based on patient profile, clinical evidence, and assessment of risk-versus-benefit.

Learning Objectives
At the conclusion of this activity, participants should be better able to:

- Evaluate current clinical evidence on precision medicine
- Define patient prognosis and risk stratification utilizing R-ISS, FISH, and imaging
- Select treatment combinations in the frontline setting based on risk and patient-specific characteristics
- Assess treatment response to induction therapy and determine which patients will benefit from consolidation and/or maintenance therapy
- Select an appropriate course of therapy for patients who have relapsed from or become refractory to initial treatment

Expiration

Jan 26, 2019

Discipline(s)

Nurse Practitioner , Physician CME, Physician Assistant CME

Format

Online

Credits / Hours

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.Penn State College of Medicine designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation

ACCME

Presenters / Authors / Faculty

Paul G. Richardson, MD—Program Co-Chair
R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

A. Keith Stewart, MBChB, MRCP, FRCPC, MBA—Program Co-Chair
Carlson and Nelson Endowed Director,
Center for Individualized Medicine
Vasek and Anna Maria Polak Professor of Cancer Research
Consultant, Division of Hematology/Oncology
Mayo Clinic
Scottsdale, Arizona

Jesus G. Berdeja, MD
Director, Multiple Myeloma Research
Senior Investigator, Hematologic Malignancies
Sarah Cannon Research Institute
Nashville, Tennessee

Nina Shah, MD
Associate Professor of Clinical Medicine
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California

Peter Voorhees, MD
Director, Outreach for Hematologic Malignancies
Plasma Cells Disorder Program
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute
Carolinas HealthCare System
Charlotte, North Carolina

Katja Weisel, MD
Professor of Internal Medicine
University Hospital Tübingen
Head, Tübingen University Myeloma Center
Tübingen, Germany

Activity Specialities / Related Topics

Education / Teaching, Hematology, Oncology / Cancer / Radiation Therapy

Sponsors / Supporters / Grant Providers

Support for this activity has been provided through educational grants from Amgen and Celgene Corporation.

Keywords / Search Terms

RedMedEd RedMedEd MMRF, MM, multiple myeloma, multiple myeloma research foundation, outcomes, disease, treatment, evidence, precision medicine, risk stratification, imaging, combinations, frontline, induction therapy, maintenance therapy, therapy, refractory, Free CME, hematollogist-oncologist, medical oncologist, free, CME Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map